Michelle Robertson Sells 2,936 Shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Stock

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) CFO Michelle Robertson sold 2,936 shares of the firm’s stock in a transaction on Friday, October 18th. The shares were sold at an average price of $13.83, for a total value of $40,604.88. Following the transaction, the chief financial officer now directly owns 16,551 shares in the company, valued at $228,900.33. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of MNTA opened at $14.58 on Wednesday. The firm has a market capitalization of $1.41 billion, a price-to-earnings ratio of -7.18 and a beta of 2.03. Momenta Pharmaceuticals, Inc. has a one year low of $9.51 and a one year high of $16.11. The stock’s fifty day moving average is $13.42 and its 200-day moving average is $12.72.

Momenta Pharmaceuticals (NASDAQ:MNTA) last issued its quarterly earnings results on Friday, August 2nd. The biotechnology company reported ($1.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.74). The business had revenue of $5.18 million for the quarter, compared to analyst estimates of $9.20 million. Momenta Pharmaceuticals had a negative net margin of 324.41% and a negative return on equity of 55.24%. Momenta Pharmaceuticals’s revenue for the quarter was down 60.2% on a year-over-year basis. During the same period last year, the business posted ($0.91) earnings per share. On average, research analysts expect that Momenta Pharmaceuticals, Inc. will post -2.52 earnings per share for the current fiscal year.

MNTA has been the topic of a number of research analyst reports. BidaskClub raised Momenta Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, October 9th. Piper Jaffray Companies set a $35.00 price target on Momenta Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, September 17th. ValuEngine lowered Momenta Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, October 15th. Finally, HC Wainwright initiated coverage on Momenta Pharmaceuticals in a report on Wednesday, September 25th. They set a “buy” rating and a $24.00 price target on the stock. Four equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $22.53.

A number of large investors have recently added to or reduced their stakes in MNTA. Marshall Wace North America L.P. acquired a new position in Momenta Pharmaceuticals during the first quarter worth about $130,000. MetLife Investment Advisors LLC grew its holdings in Momenta Pharmaceuticals by 22.8% during the first quarter. MetLife Investment Advisors LLC now owns 43,796 shares of the biotechnology company’s stock worth $636,000 after acquiring an additional 8,123 shares during the period. Metropolitan Life Insurance Co NY grew its holdings in Momenta Pharmaceuticals by 19.3% during the first quarter. Metropolitan Life Insurance Co NY now owns 31,425 shares of the biotechnology company’s stock worth $456,000 after acquiring an additional 5,094 shares during the period. Oregon Public Employees Retirement Fund grew its holdings in Momenta Pharmaceuticals by 5.6% during the second quarter. Oregon Public Employees Retirement Fund now owns 39,254 shares of the biotechnology company’s stock worth $489,000 after acquiring an additional 2,074 shares during the period. Finally, CWM Advisors LLC grew its holdings in Momenta Pharmaceuticals by 17.2% during the second quarter. CWM Advisors LLC now owns 13,780 shares of the biotechnology company’s stock worth $172,000 after acquiring an additional 2,020 shares during the period. 96.29% of the stock is currently owned by hedge funds and other institutional investors.

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy.

Read More: The limitations of an equal weight rating

Insider Buying and Selling by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.